DRRX (DURECT) Earnings per share for the last twelve months

Public company logo of DURECT Corporation (DRRX)

Anticipation of the final test results for the primary hepatitis drug will serve as a key trigger, while the EPS metric on the GURU.Markets platform stands at -9.40. This price chart helps track the biotech business developing Larsucosterol for internal organ therapy. The DURECT Corporation (DRRX) strategy relies on epigenetic control, enabling the treatment of critical liver failure without organ transplantation and establishing a unique medical standard.

DURECT (DRRX): Earnings per share for the last twelve months from 02/11/2024 to 02/20/2024

Financial and market metric breakdowns for DURECT Corporation (DRRX)

- market price and analyst price targets:
- business market valuation indicators:
Initial company analysis:DURECT Corp DRRX
Finished products of DURECT Corp.

Year-over-year EPS growth (TTM) measures the percentage change in earnings per share over twelve months, reflecting the business's capitalization efficiency and profitability dynamics. By analyzing the annual change in net income per share over a rolling period, an investor assesses the sustainability of the DURECT Corporation (DRRX) model, where progress in the development of the DUR-928 drug for liver regeneration could radically transform the company's financial performance.